financetom
Business
financetom
/
Business
/
Plus Therapeutics Shares Jump After FDA Accepts Name of Lead Tumor Treatment Candidate
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Plus Therapeutics Shares Jump After FDA Accepts Name of Lead Tumor Treatment Candidate
Mar 20, 2025 11:14 AM

01:52 PM EDT, 03/20/2025 (MT Newswires) -- Plus Therapeutics ( PSTV ) shares jumped nearly 183% in recent trading Thursday after the company said the US Food and Drug Administration conditionally accepted the proprietary name for its lead tumor therapy candidate.

The medicine will be known as Reyobiq and will be subject to a proprietary name review once a new drug application is submitted, Plus Therapeutics ( PSTV ) said.

The company is developing Reyobiq as an injectable radiotherapy to treat central nervous system tumors.

Price: 1.45, Change: +0.93, Percent Change: +182.78

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved